Promore Pharma AB (publ) Year-end report 2019
October to December 2019 · Net sales amounted to 1.5 (1.4) MSEK. · The operating loss for the period was 9.4 (-6.5) MSEK · Net loss was 9.4 (-7.2) MSEK, corresponding to a loss per share of SEK 0.38 (-0.35) · Cash flow from operating activities amounted to -0.3 (-8.7) MSEK · Cash and cash equivalents amounted to 60.5 (30.9) MSEK January to December 2019 · Net sales amounted to 3.9 (2.4) MSEK. · The operating loss for the period was 29.1 MSEK (-32.7) MSEK · Net loss was 28.9 (-32.5) MSEK, corresponding to a loss per share of SEK 1.16 (-1.61) · Cash flow from